Physician profile
Harold M Lin
NPI 1467472472
$4,066.49
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,163 · 2020: $736 · 2021: $1,119 · 2022: $48.03.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,283.71 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $881.80 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $647.76 | 2019-2021 | |
| Lilly USA, LLC | $406.64 | 2019-2021 | |
| Novo Nordisk INC | $324.88 | 2019-2022 | |
| Amarin Pharma, INC. | $144.32 | 2019 | |
| Glaxosmithkline, LLC. | $123.40 | 2021 | |
| Medtronic USA, INC. | $121.71 | 2019 | |
| Merck Sharp & Dohme LLC | $114.67 | 2019 | |
| Esperion Therapeutics, INC. | $17.60 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harold Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.